Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research
Hani Rustom posted on LinkedIn
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal
Medicina | Free Full-Text | The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern | Fluids and Barriers of the CNS
Discrepancy in serum free light chain analysis compared with serum... | Download Scientific Diagram
Sebia launches new-generation serum free light chain (sFLC) assays for multiple myeloma testing | Andrew Lloyd & Associates
SEBIA FLC - serum free light chain quantification
Measurement of kappa (κ) and lambda (λ) light chains in free and total... | Download Scientific Diagram
Human Kappa and Lambda Free Light Chain Control - Sekisui Diagnostics
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal
Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument - ScienceDirect
Sebia FLC Kappa, Serum free light chain quantification
Kappa/lambda serum FLC ratio in patients with IgG4-RD. Comparison of... | Download Scientific Diagram
Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument - ScienceDirect
Table 3 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
Comparison of Sebia FLC with N Latex FLC and Freelite in the... | Download Scientific Diagram
Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma | Blood Cancer Journal
November 18, 2022 Sebia, Inc. Karen Anderson Director of Regulatory 1705 Corporate Drive, Suite 400 Norcross, Georgia 30093 Re:
Next generation free light chain assay - Clinical Laboratory int.
